Research progress of MUC1 in genitourinary cancers

Table 1 MUC1-based clinical trials

Cancer type	Biological	Composition and targets	Study phase	Trial number	Status	Year	Enrollment
Bladder cancer	PANVAC	CEA-MUC1-TRICOM	II	NCT02015104	Completed	2013	32
	CV301	CEA, MUC1, ICAM-1, LFA-3, and B7-1	II	NCT03628716	Halted	2018	43
	Dendritic cells	MUC1	II	NCT04184232	Completed	2019	17
Renal cell carcinoma	Vaccine	MUC1, CEA, Her2/neu, telomerase, survivin, MAGE-A1	I/II		Completed	2003	30
	TG4010	MUC1-IL2	II		Completed	2003	37
	Antibody	Anti-CD3-MUC1	II	NCT03540199	Withdrawn	2018	0
	Dendritic cells	MUC1-PADRE	I/II		Completed	2020	20
	CAR-T cells	P-MUC1C-ALLO1	I	NCT05239143	Recruiting	2022	100
Prostate cancer	Vaccine	VV/MUC-1/IL-2	I		Completed	1998	22
	Vaccine	MUC1-KLH	I	NCT00005632	Completed	1999	27
	TG4010	MUC1-IL2	II	NCT00040170	Terminated	2002	40
	Vaccine	MUC1	I	NCT00374049	Completed	2006	14
	Dendritic cells	Tn-MUC1	I/II	NCT00852007	Completed	2009	20
	L-BLP25	MUC1	II	NCT01496131	Completed	2011	28
	CV9104	PSA, PSMA, PSCA, STEAP, PAP, and MUC1	I/II	NCT01817738	Terminated	2012	197
	Vaccine	Ad-sig-hMUC1/ecdCD40L	I	NCT02140996	Unknown	2014	24
	CV9104	PSA, PSMA, PSCA, STEAP, PAP, and MUC1	II	NCT02140138	Terminated	2014	35
	Dendritic cells	NY-ESO-1, MAGE-C2, and MUC1	II	NCT02692976	Completed	2015	21
	Vaccine	Ad5 CEA/MUC1/Brachyury	I	NCT03384316	Completed	2018	11
	Vaccine	Ad5 PSA/MUC1/brachyury	I	NCT03481816	Completed	2018	18

ISSN: 1689-1392